Status:
COMPLETED
Safety Study of Anti-IgE Immunotherapy in Allergic Patients
Lead Sponsor:
Resistentia Pharmaceuticals AB
Conditions:
Allergy
Eligibility:
MALE
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of the study is to evaluate safety and efficacy of three doses and two dosing regimens of RP01 as an anti-IgE immunotherapy in allergic patients.
Detailed Description
Immunotherapy is based on the principle of eliciting an immune reaction in order to block the negative effect of a specific disease-causing protein. The potential to treat diseases by means of immunot...
Eligibility Criteria
Inclusion
- Allergy to at least one aero allergen
- Increased serum IgE level
Exclusion
- Diagnosis of asthma
- Recent use of systemic corticosteroids or immunosuppressive treatment
- Allergy vaccination therapy
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00439621
Start Date
February 1 2007
End Date
August 1 2008
Last Update
August 18 2008
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
P3 Research
Tauranga, New Zealand
2
P3 Research
Wellington, New Zealand